These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26209999)

  • 1. Benefits of less frequent injections in advanced prostate cancer.
    Ortiz M
    Aust Fam Physician; 2015 Jun; 44(6):429-30. PubMed ID: 26209999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuprorelin acetate in prostate cancer: a European update.
    Persad R
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.
    Sharifi R; Browneller R;
    J Urol; 2002 Sep; 168(3):1001-4. PubMed ID: 12187208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
    Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J; Davis R; Frankel D; Kold Olesen T
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
    J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
    Crawford ED; Moul JW; Sartor O; Shore ND
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What should I know about Lupron Depot for treating prostate cancer?
    Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
    [No Abstract]   [Full Text] [Related]  

  • 11. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
    Sethi R; Sanfilippo N
    Clin Interv Aging; 2009; 4():259-67. PubMed ID: 19554097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Are all LH-RH analogues equally effective in prostate cancer?].
    Fosså SD
    Tidsskr Nor Laegeforen; 2005 Sep; 125(18):2493-5. PubMed ID: 16186869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
    Moul JW; Civitelli K
    Urol Nurs; 2001 Dec; 21(6):385-8, 393-4; quiz 395-6. PubMed ID: 11998504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment.
    Herranz Amo F
    Arch Esp Urol; 2010 May; 63(4):275-81. PubMed ID: 20508303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 17. Granulomas induced by subcutaneous injection of leuprorelin acetate.
    Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
    J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.
    Fowler JE; Flanagan M; Gleason DM; Klimberg IW; Gottesman JE; Sharifi R
    Urology; 2000 May; 55(5):639-42. PubMed ID: 10792069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Granulomas induced by injections of leuprorelin acetate (Enantone®)].
    Bruneu-Avierinos Y; Monestier S; Tasei AM; Gaudy-Marqueste C; Grob JJ; Richard MA
    Ann Dermatol Venereol; 2011 Jan; 138(1):35-7. PubMed ID: 21276459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.